Abstract:Management of moderate to severe pain relies heavily on opioid analgesics such as morphine, oxycodone, and fentanyl in clinics. However, their prolonged use was associated with undesirable side effects. Many new strategies to reduce side effects have been proposed, but not without disadvantages. Using a hot plate model as a phenotypic screening method, our studies identified (3R,4S)-9d with a new scaffold as a potent analgesic with ED50 values of 0.54 mg/kg and 0.021 mg/kg in hot plate and antiwrithing models, respectively. Mechanistic studies showed that it elicited its analgesic effect via the active metabolite (3R,4S)-10a. The mechanism of (3R,4S)-10a-induced activation of the μ opioid receptor (MOR) was proposed by means of molecular dynamics (MD) simulation.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00722?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00722</a>.Active murine MOR, PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5C1M">5C1M</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00722/suppl_file/jm1c00722_si_001.pdb">PDB</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00722/suppl_file/jm1c00722_si_002.csv">CSV</a>)Screening of resolution of 4c; optimization of the resolution procedure of 4c; HPLC spectrum of 4c and its enantiomers; experimental and theoretical ECD; In vivo metabolism assay; potential energy and RMSD evolution during MD simulation; 1H NMR and 13C NMR spectra of final compounds; HPLC spectra of key compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00722/suppl_file/jm1c00722_si_003.pdf">PDF</a>)This article has not yet been cited by other publications.

Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.

Synthesis and Analgesic Activity of Secondary Amine Analogues of Pyridylmethylamine and Positional Isomeric Analogues of ABT-594

Discovery, Structure–Activity Relationship, and Mechanistic Studies of 1-((3 R ,4 S )-3-((Dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)ethan-1-one as a Novel Potent Analgesic

Discovery, Structure-Activity Relationship, and Mechanistic Studies of 1-((3R,4s)-3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)ethan-1-one As a Novel Potent Analgesic.

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.

Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a Mu Opioid Receptor Agonist/Delta Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.

Synthesis and Structure-Activity Relationships of 5-Aryl-14-alkoxypyridomorphinans: Identification of a Opioid Receptor Agonist/ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects

Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability Via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues

Design, Synthesis, and Structure–Activity Relationship Exploration of Alkyl/Phenylalkyl Piperidine Analogues As Novel Highly Potent and Selective Μ Opioid Receptor Agonists

Novel selective κ agonists SLL-039 and SLL-1206 produce potent antinociception with fewer sedation and aversion

Design, Synthesis and SAR Exploration of Alkyl/PhenylalkylPiperidine Analogues As Novel Highly Potent and Selective MOR Agonists.

Chemistry And Pharmacological Characterization Of Novel Nitrogen Analogues Of Amop-H-Oh (Sazetidine-A, 6[5-(Azetidin-2-Ylmethoxy)Pyridin-3-Yl]Hex-5-Yn-L-Ol) As Alpha 4 Beta 2-Nicotinic Acetylcholine Receptor-Selective Partial Agonists

Isoquinolone derivatives as lysophosphatidic acid receptor 5 (LPA5) antagonists: Investigation of structure-activity relationships, ADME properties and analgesic effects

Discovery of 3-((Dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)-n-phenylpiperidine-1-carboxamide As Novel Potent Analgesic.

Synthesis and Structure–Activity Relationship Studies of Benzimidazole-4,7-dione-Based P2X3 Receptor Antagonists as Novel Anti-Nociceptive Agents

Synthesis And Structure-Activity Relationships Of Pyridine-Modified Analogs Of 3-[2-((S)-Pyrrolidinyl)Methoxy]Pyridine, A-84543, A Potent Nicotinic Acetylcholine Receptor Agonist

Synthesis and Evaluation of Κ-Opioid Receptor Agonistic Activity and Antinociceptive Effect of Novel Morphine Analogues, 7Α-Phenyl-6α,14α-endo-etheno-tetrahydrothebaine with Substituted O-, M- and P-Amino Group

3-Pyrroline containing arylacetamides

Discovery of a highly selective and potent kappa opioid receptor agonist from N-cyclopropylmethyl-7α-phenyl-6,14-endoethano-tetrahydro- northebaines with reduced central nervous system (CNS) side effects navigated by the message-address concept.

3-Pyrroline containing arylacetamides: a novel series of remarkably selective kappa-agonists.